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Abstract   106 
Background – Stroke patients with unknown time of onset have been previously excluded 107 
from thrombolysis. We aimed to determine whether intravenous alteplase is safe and 108 
effective in these patients when salvageable tissue is identified using imaging biomarkers. 109 
Methods – We performed a systematic review and meta-analysis of individual patient data of 110 
trials published before 21 September 2020. Randomized trials of intravenous alteplase 111 
versus standard of care or placebo in adults with unknown onset stroke using perfusion-112 
diffusion MRI, perfusion CT, or MRI with DWI-FLAIR mismatch were eligible. The primary 113 
outcome was favourable functional outcome (score of 0-1 on the modified Rankin Scale 114 
[mRS]) at 90 days indicating no disability, secondary outcomes were mRS shift towards a 115 
better functional outcome and independent outcome (score 0-2 on the mRS) at 90 days. 116 
Safety outcomes included death, severe disability or death (mRS 4-6), and symptomatic 117 
intracerebral haemorrhage (sICH). The study is registered with PROSPERO, number 118 
CRD42020166903. 119 
Findings – Four trials met the eligibility criteria: WAKE-UP, EXTEND, THAWS, and ECASS-120 
4. Of the 843 patients, 429 (51%) were assigned to alteplase and 414 (49%) to placebo or 121 
standard care. A favourable outcome occurred in 199 of 420 patients (47%) with alteplase 122 
and in 160 of 409 patients (39%) among controls (adjusted odds ratio [aOR] 1.50, 95% 123 
confidence interval [CI] 1.10-2.04, p=0.010). Alteplase was associated with a significant shift 124 
towards better functional outcome (adjusted common odds ratio 1.38, 95% CI 1.05-1.80, 125 
p=0.019), and with a higher odds of independent outcome (aOR 1.50, 95% CI 1.06-2.12). In 126 
the alteplase group, 90 patients (21%) reached the safety endpoint of being severely 127 
disabled or dead (mRS 4-6), compared to 102 patients (25%) in the control group (aOR 0.76, 128 
95% CI 0.52-1.11, p=0.15). Death occurred in 27 patients (6%) with alteplase and in 14 129 
patients (3%) among controls (aOR 2.06, 95% CI 1.03-4.09, p=0.040). sICH was higher with 130 
alteplase than among controls (11 [3%] vs. 2 [1%], aOR 5.58, 95% CI1.22-25.50, p=0.024).  131 
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Interpretation – In stroke patients with unknown time of onset with a DWI-FLAIR or perfusion 132 
mismatch, intravenous alteplase resulted in better functional outcome at 90 days than 133 
placebo or standard care. A net benefit was observed for all functional outcomes despite an 134 
increased risk of sICH. While there were numerically higher rates of death with alteplase, 135 
rates of severe disability or death were numerically lower in the alteplase group.  136 
Funding – None 137 
  138 
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Intravenous thrombolysis with alteplase is standard of care for acute ischemic stroke. It 139 
improves functional outcome and is more effective the earlier treatment is initiated 1. Since its 140 
first approval for stroke treatment, intravenous alteplase was restricted to patients with 141 
known time of symptom onset within a narrow time window. This was initially less than 3 142 
hours of symptom onset based on the results of the NINDS trial 2and was extended to a time 143 
window of less than 4.5 hours following the positive results of ECASS-3 3 and subsequent 144 
meta-analysis 1,4. Patients with unknown time of symptom onset were excluded from 145 
randomized controlled trials of intravenous thrombolysis for stroke and from thrombolytic 146 
treatment in clinical practice. 147 
The time of symptom onset is unknown in up to 20-25% of stroke patients, mostly due to 148 
symptoms being recognized after waking-up from overnight sleep, but also for other reasons 149 
such as unwitnessed stroke with aphasia or disturbed level of consciousness. In recent 150 
years, several clinical studies have been designed to solve this clinical problem by testing 151 
treatment with intravenous thrombolysis based on selection using imaging biomarkers in 152 
patients with unknown time of stroke onset by using either penumbral imaging (i.e., 153 
perfusion-diffusion MRI or perfusion CT) or MRI-based tissue-clocking, i.e. the mismatch 154 
between a visible ischemic lesion on diffusion-weighted imaging (DWI) while there is no 155 
marked parenchymal hyperintensity on fluid-attenuated inversion recovery (FLAIR) on MRI 156 
(DWI-FLAIR mismatch) 5. The WAKE-UP trial provided evidence of benefit of treatment with 157 
intravenous alteplase in patients with unknown onset stroke if the treatment decision was 158 
based on DWI-FLAIR mismatch 6. Current US and European guidelines and consensus 159 
statements recommend intravenous thrombolysis with alteplase in patients with unknown 160 
time of symptom onset if patients meet the WAKE-UP criteria 7,8. Based on selection with MR 161 
or CT perfusion imaging, the EXTEND trial also showed better functional outcome in 162 
alteplase-treated patients awakening with stroke or treated from 4.5 to 9.0 hours after 163 
symptom onset 9.  164 
 165 
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Both WAKE-UP and EXTEND were started before compelling evidence for stroke 166 
thrombectomy was available and both excluded patients in whom thrombectomy was 167 
planned. In the meantime, two trials of endovascular stroke treatment, DAWN and DEFUSE-168 
3, provided evidence of a benefit of mechanical thrombectomy guided by penumbral imaging 169 
in a late or unknown time-window 10,11.  170 
Nevertheless, the individual trials were still modest in size and there is limited knowledge on 171 
efficacy and safety of thrombolysis in subgroups of patients with an unknown time of stroke 172 
onset. A recent individual patient-data meta-analysis of the trials using penumbral imaging to 173 
guide intravenous thrombolysis in patients in an extended or unknown time window 174 
(EXTEND, ECASS4, and EPITHET) indicated that intravenous alteplase improves functional 175 
outcome in these patients (n=414), with an overall net clinical benefit despite an increase of 176 
the rate of symptomatic intracranial haemorrhage (sICH) and a numerical but non-significant 177 
increase in deaths in the thrombolysis group 12.We aimed to determine whether intravenous 178 
alteplase is safe and effective in patients with unknown time of onset stroke when 179 
salvageable tissue is identified using based on imaging biomarkers. To this end, we 180 
performed a meta-analysis of individual patient data (n=843) to test the hypothesis that 181 
intravenous alteplase improves functional outcomes compared with placebo or standard of 182 
care in patients with acute ischemic stroke with an unknown time of onset if selected using 183 
imaging biomarkers including either DWI-FLAIR mismatch or CT or MRI based penumbral 184 
imaging. 185 
 186 
Methods  187 
Search strategy and selection criteria 188 
For the systematic review we searched PubMed, Web of Science, SciELO, and LILACS for 189 
clinical trials published before 21 September 2020 with the following search terms: “stroke” 190 
AND (“alteplase” OR “rtPA” OR “tPA” OR “thrombolysis”) AND (“randomised” OR 191 
“randomized”) AND (“unknown” OR “unwitnessed” OR “wake-up” OR “extended”) (filters 192 
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activated: “Clinical Trial”, “Humans”). Randomized trials of intravenous alteplase versus 193 
standard of care or placebo in adults (≥ 18 years of age) with acute ischemic stroke and 194 
unknown time of symptom onset using advanced brain imaging with either penumbral 195 
imaging (i.e., perfusion-diffusion MRI or perfusion CT) or MRI-based tissue-clocking (i.e., 196 
DWI-FLAIR mismatch) with >20 patients enrolled were eligible for inclusion. We further 197 
searched ClinicalTrials.gov, the European Union Clinical Trials Register, the World Health 198 
Organization International Clinical Trials Registry Platform, the ISRCTN Registry, and the 199 
Cochrane Central Register of Controlled Trials for clinical trials of intravenous alteplase in 200 
unknown onset stroke. All patients included in the primary analyses of individual trials were 201 
considered eligible for inclusion in the meta-analysis. Two reviewers (BC and GT) 202 
independently reviewed articles and reached a unanimous decision for inclusion. 203 
The steering committees of all included trials agreed to join the Evaluation of unknown Onset 204 
Stroke thrombolysis trials (EOS) collaboration and share individual patient-level data for 205 
meta-analysis. Ethical approval was obtained for all participating sites for all included trials, 206 
and patients or their legal representatives provided written informed consent according to 207 
national and local regulations including an exception from explicit informed consent in 208 
emergency circumstances in some countries. The protocol for this study was prespecified 209 
and followed PRISMA guidelines for meta-analysis of individual patient data (see appendix). 210 
The study is registered with PROSPERO, number CRD42020166903). 211 
 212 
Outcomes  213 
The prespecified primary outcome was a favourable outcome defined by a score of 0-1 on 214 
the modified Rankin Scale (mRS, which ranges from 0 [no symptoms] to 6 [death]) at 90 215 
days after stroke. This identifies patients with no symptoms at all (mRS 0) or only minimal 216 
symptoms with no significant disability, being able to carry out all usual activities (mRS 1).  217 
Secondary outcomes were functional improvement across the entire mRS (i.e., mRS shift 218 
analysis) at 90 days and independent outcome defined by a score of 0-2 on the mRS at 90 219 
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days. Safety outcomes were death, severe disability or death (i.e., mRS 4-6), sICH according 220 
to the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS–MOST) 13 and 221 
radiologically defined parenchymal haemorrhage type 2 (PH-2) 14. Additional outcomes were 222 
death within 7 days of randomization and death or dependence (i.e., MRS 3-6) at 90 days.  223 
 224 
Imaging data 225 
We reanalysed all available imaging data as follows. Judgement of vessel occlusion was 226 
based on image readings provided by the individual trials. Any vessel occlusion was defined 227 
as any visible occlusion of an intracranial brain supplying artery on baseline MR- or CT-228 
angiography. Large vessel occlusion was defined as occlusion of the intracranial internal 229 
carotid artery or main stem of the middle cerebral artery. Penumbral mismatch was defined 230 
according to the criteria used in recent studies of intravenous alteplase based on perfusion 231 
mismatch 12. Penumbral mismatch was considered present with a mismatch ratio between 232 
critically hypoperfused tissue and infarct core >1.2, a mismatch volume greater than 10 ml, 233 
and an ischemic core volume less than 70 ml. Critically hypoperfused tissue was defined as 234 
tissue with a time to maximum (Tmax) >6 s in CT perfusion or MR perfusion. Infarct core was 235 
defined as a relative cerebral blood flow <30% of contralateral cerebral blood flow for CT 236 
perfusion or an apparent diffusion coefficient of less than 620 μm²/s for diffusion MRI. CT 237 
perfusion and MR perfusion and DWI data, if available, were reprocessed using automated 238 
processing software RAPID (version 4.6, 4.9 and 5.0; iSchemaView, Menlo Park, CA, USA) 239 
as described previously 10,11. DWI-FLAIR mismatch was defined according to the criteria 240 
used in the WAKE-UP trial, i.e., a mismatch between an acute ischemic lesion visible on DWI 241 
and no marked parenchymal hyperintensity on FLAIR in the corresponding region as 242 
assessed by visual inspection 15. 243 
 244 
Data Analysis  245 
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The full statistical analysis plan is provided in the appendix. The responsible statisticians 246 
from each trial extracted the patient-level data from the trial databases on the basis of data 247 
fields pre-specified in the study protocol (see supplementary methods in the appendix). The 248 
responsible biostatistician for the meta-analysis (FB) collated all data from the individual trials 249 
and cross-checked them against the original publications of the individual trials.  250 
The modified Cochrane Collaboration tool to assess risk of bias for randomized controlled 251 
trials was applied for qualitative assessment of between trial differences including patient 252 
eligibility and assessment of bias (see appendix). 253 
This meta-analysis followed a one-stage approach with the use of relevant mixed-effect 254 
logistic regression models with "trial" as a random intercept effect and “treatment 255 
assignment” as a random slope effect, allowing the treatment effect to vary across trials. As 256 
randomization in the WAKE-UP trial was stratified on age (≤60/>60 years) and severity of 257 
symptoms (National Institute of Health Stroke Scale [NIHSS] ≤10/>10) at baseline, all models 258 
were adjusted on these two categorical covariates. All outcomes were assessed in the 259 
intention-to-treat population, i.e., all randomized patients assigned to their randomized 260 
treatment group. 261 
The primary efficacy outcome was analysed using an unconditional mixed-effect logistic-262 
regression model fitted to estimate the treatment effect, reported as an odds ratio (OR) and 263 
its 95% confidence interval (CI). Missing primary outcome values were replaced using 264 
multiple imputation including the following covariates: allocated treatment, baseline age 265 
(continuous), baseline NIHSS score, and NIHSS score at day 7. We also performed a 266 
sensitivity analysis without replacement of missing outcomes. The heterogeneity of treatment 267 
effect across trials was tested using the Cochran’s Q-statistic. We also report the I² statistic 268 
describing the percentage of variation across studies that is due to heterogeneity rather than 269 
chance 16. 270 
The categorical shift in the distribution of mRS scores between the two treatment groups was 271 
analysed fitting a proportional-odds logistic regression model, assuming a common OR 272 
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across all cut points of the mRS with values 5 and 6 collapsed into one category to prevent 273 
interpreting mRS 5 as a better outcome than mRS 6. Prior to performing ordinal regression 274 
analysis, we tested the proportional odds assumption. Analysis of independent outcome, 275 
death, and severe disability or death was performed using the same unconditional mixed-276 
effect logistic-regression model as for the primary outcome. SICH and PH-2 were analysed 277 
with two-by-two tables stratified by trials and the common Cochran- Mantel-Haenszel OR 278 
and its 95% CI were calculated. The Breslow-Day test was used to test homogeneity of OR 279 
across trials. For secondary and safety outcomes missing values were not replaced. 280 
We performed pre-planned analyses in the following subgroups: use of standard dose (0.9 281 
mg/kg bodyweight) vs. low dose (0.6 mg/kg bodyweight) alteplase; age (≤60 vs >60 years); 282 
sex; baseline stroke severity (NIHSS ≤10 vs >10); any visualized vessel occlusion; large 283 
vessel occlusion; imaging modality (CT vs MRI); history of AF; history of stroke or TIA; prior 284 
antiplatelet use; delay from symptom recognition to treatment (≤3 vs >3 hours); penumbral 285 
mismatch present; DWI-FLAIR mismatch present. For all subgroup analyses, the same 286 
model as for the analysis of the primary outcome was used, with an additional interaction 287 
parameter between the treatment and the subgroup covariate entered as a fixed effect. 288 
In an additional analysis, we included available data on outcome and safety of intravenous 289 
alteplase in unknown onset stroke from single-arm studies. 290 
All analyses were performed with a two-sided alpha level of 0.05. There was no correction of 291 
the alpha-level for multiple comparisons. Statistical analysis was done using SAS software 292 
(version 9.4, Windows) and R-software (version 3.3.2). 293 
 294 
Role of the funding source 295 
There was no funding source for this meta-analysis. The funders of the trials included in this 296 
meta-analysis (WAKE-UP, EXTEND, THAWS, ECASS4) had no role in study design, data 297 
collection, data analysis, data interpretation, or writing of this report. The corresponding 298 
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author had full access to all the data in the study and had final responsibility for the decision 299 
to submit for publication. 300 
 301 
Results 302 
Our search strategy identified four randomized trials that met the eligibility criteria: WAKE-303 
UP6, EXTEND9, THAWS17, and ECASS-418 (for the PRISMA IPD flow diagram see 304 
supplemental figure 1 in the appendix). All four trials applied brain imaging beyond non-305 
contrast CT to randomize either exclusively patients with unknown onset stroke, or patients 306 
within an extended time window beyond 4.5 hours of symptom onset including unknown 307 
onset stroke, to intravenous alteplase or placebo/standard of care.  308 
WAKE-UP was a European randomized placebo-controlled trial that used MRI with DWI-309 
FLAIR mismatch to guide standard dose intravenous alteplase in patients with unknown 310 
onset stroke 6. While not mandatory, MR perfusion data were acquired in a subgroup of 311 
patients randomized and available for assessment of penumbral mismatch. EXTEND was a 312 
trial in Australia, New Zealand, Asia, and Finland that used penumbral imaging with either CT 313 
perfusion or perfusion-diffusion MRI to randomize patients in an extended time window 4.5-9 314 
hours of stroke or wake-up stroke (if the midpoint between the time last known well and time 315 
of waking up with symptoms was within 9 hours) to standard dose alteplase or placebo 9. 316 
THAWS was a Japanese trial using MRI with DWI-FLAIR mismatch according to WAKE-UP 317 
to randomize patients to a reduced dose of 0.6 mg/kg alteplase (i.e., the approved dose in 318 
Japan) 19 or standard of care 17. ECASS-4 was a European trial that applied the same 319 
eligibility criteria as EXTEND but used only perfusion-diffusion MRI (not CT) to randomize 320 
patients to standard dose alteplase or placebo 18. ECASS-4 data were also available for 321 
assessment of DWI-FLAIR mismatch. WAKE-UP was terminated early due to cessation of 322 
funding. EXTEND and THAWS were stopped early after publication of the positive results of 323 
the WAKE-UP trial due to lack of equipoise, and ECASS-4 was terminated early due to 324 
reduced recruitment following the publication of the positive trials of thrombectomy in an 325 
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extended time-window 10,11. These four trials were included in the primary analysis. 326 
Importantly, from EXTEND and ECASS-4, we only included patients with unknown-onset 327 
stroke for this meta-analysis. Overall, the risk of bias in the studies included in the meta-328 
analysis was considered low (see table S2 in the supplementary appendix). For baseline 329 
characteristics of individual trials see table S3 in the supplementary appendix. Our search 330 
strategy identified another study, which met eligibility criteria except for not being a 331 
randomized clinical trial, MR WITNESS20 which we included in a supplementary safety 332 
analysis.  333 
We obtained data from all 843 participants with unknown onset stroke randomized in the four 334 
trials included in the primary analysis. Of these, 429 (51%) were assigned to receive 335 
alteplase and 414 (49%) to receive placebo or standard of care. Baseline characteristics 336 
were balanced between the groups (table 1). 337 
Mean age was 68.5 years (standard deviation [SD] 12.5), 322 (38%) were female. Waking 338 
from overnight sleep was the reason for unknown symptom onset in 751 patients (89%). 339 
Median time from last seen well to symptom recognition was 7.0 hours (interquartile range 340 
[IQR] 5.0-9.0). Median NIHSS on admission was 7 (IQR 4-12). MRI was used for 341 
randomization in 714 patients (85%). A DWI-FLAIR mismatch was present in 642 of 679 342 
patients (95%) in whom assessment of DWI-FLAIR mismatch was performed. Penumbral 343 
mismatch was present in 211 of 405 patients (52%) in whom perfusion imaging was carried 344 
out. Any vessel occlusion was present in 342 of 771 patients (44%) in whom information on 345 
vessel status was available, and 189 of them had large vessel occlusion (24%). 346 
Primary outcome data were available for 829 of 843 patients included in the analysis (420 of 347 
429 patients in the alteplase group and 409 of 414 patients in the control group). We used 348 
three covariates to impute the missing primary outcome in 14 patients, two were stratification 349 
variables (age and NIHSS score at baseline) with no missing data, and one was NIHSS 350 
score at 72 hours, for which 36 missing values were imputed. 351 
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A favourable outcome (mRS score 0-1) at 90 days was observed in 199 of 420 patients 352 
(47%) in the alteplase group and in 160 of 409 patients (39%) in the control group (adjusted 353 
OR [aOR] 1.49, 95% CI 1.10-2.03, p=0.011; figure 1, table 2). Treatment with alteplase was 354 
associated with a significant shift towards better functional outcome, i.e., lower scores on the 355 
mRS at 90 days in ordinal analysis (adjusted common OR [acOR] 1.38, 95% CI 1.05-1.80, 356 
p=0.019). The proportion of patients achieving functional independence (mRS score 0-2) at 357 
90 days was also significantly higher in the alteplase group than in the control group (aOR 358 
1.50, 95% CI 1.06-2.12, p=0.022). Sensitivity analysis without replacement of primary 359 
outcome confirmed a significant benefit of alteplase on the primary endpoint (see 360 
supplementary results in the supplementary appendix). 361 
At 90 days, death was reported in 27 patients (6%) in the alteplase as compared to 14 362 
patients (3%) in the control group (aOR 2.06, 95% CI 1.03-4.09, p=0.04). Of the 27 deaths in 363 
the alteplase group, 7 were attributable to sICH, 4 to recurrent or progressive stroke, 2 were 364 
of unknown cause, and the remaining 14 deaths were of non-neurological cause and 365 
unrelated to treatment or index stroke. In the control group, all 14 deaths were of non-366 
neurological cause and unrelated to treatment or index stroke. Death within seven days 367 
occurred in 10 patients (2%) in the alteplase group and in 4 patients (1%) in the control group 368 
(aOR 2.54, 95% CI 0.78-8.32, p=0.19). In the alteplase group, 90 patients (21%) reached the 369 
safety endpoint of being severely disabled or dead (mRS 4-6), compared to 102 patients 370 
(25%) in the control group (aOR 0.76, 95% CI 0.52-1.11, p=0.15). The proportion of patients 371 
being dependent or dead (MRS 3-6) at 90 days was lower with alteplase than in controls 372 
(aOR 0.67, 95% CI 0.47-0.94, p=0.022). The number of patients with sICH was higher in the 373 
alteplase group than in the control group (11 [3%] vs. 2 [<1%], aOR 5.58, 95% CI1.22-25.50, 374 
p=0.024). Rates of radiologically defined PH-2 were numerically higher in the alteplase group 375 
than control 11 [3%] vs. 3 [1%], aOR 3.51, 95% CI 0.98-12.60, p=0.068). 376 
A sensitivity analysis excluding THAWS, being the only trial that used a lower dose of 377 
alteplase, revealed similar findings with a significant benefit of alteplase for the primary 378 
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endpoint and secondary efficacy endpoints, despite a numerically higher number of deaths 379 
with alteplase (see supplementary results in the supplementary appendix). 380 
Prespecified subgroup analyses for the primary outcome are shown in figure 2. There was no 381 
evidence of significant heterogeneity of the treatment effect across any of the following 382 
variables: dose of alteplase (0.9 vs. 0.6 mg/kg bodyweight), age (≤60 vs >60 years), sex, 383 
baseline stroke severity (NIHSS ≤10 vs >10), any vessel occlusion, large vessel occlusion, 384 
imaging modality (CT vs MRI), history of AF, prior antiplatelet use, delay from symptom 385 
recognition to treatment (≤3 vs >3 hours), penumbral mismatch present, or DWI-FLAIR 386 
mismatch present. Significant heterogeneity of treatment effect was observed for history of 387 
TIA or stroke with larger benefit in the subgroup of patients with history of stroke and TIA (p 388 
for interaction = 0.02).  389 
Subgroup analyses for secondary outcomes and safety outcome are provided in the 390 
appendix. We observed no evidence of heterogeneity of treatment effect across any of the 391 
subgroups for mortality. Due to the overall small numbers of sICH and PH-2, we did not 392 
perform a subgroup analysis on these two safety parameters. 393 
Adding data from the single-arm MR WITNESS trial to the analysis did not alter the main 394 
findings (see supplementary appendix).  395 
 396 
Discussion 397 
This meta-analysis of individual patient data from four randomized controlled trials showed 398 
that intravenous alteplase is beneficial in patients with unknown onset stroke selected by 399 
imaging biomarkers using MRI or CT perfusion. Patients with stroke of unknown onset time, 400 
who had a DWI-FLAIR mismatch on MRI or a penumbral mismatch on perfusion-diffusion 401 
MRI or CT perfusion and who received intravenous alteplase had higher likelihood of a 402 
favourable functional outcome at 90 days after stroke compared with controls. Rates of 403 
severe disability or death (MRS 4-6) were numerically lower with alteplase, but treatment 404 
with alteplase was associated with a small but significant increase in the rate of sICH and a 405 
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numerical but non-significant increase in mortality. The lower number of deaths in the control 406 
group (mRS 6) was offset by an increased proportion of bedridden or nursing home 407 
outcomes (mRS 5), (mRS 5 and 6) in the alteplase and control groups. Importantly, there 408 
was a significant net and clinically important benefit of intravenous alteplase across the entire 409 
range of functional outcome in ordinal analysis of the mRS.  410 
Our analysis strengthens the results of individual trials and extends the information on 411 
treatment effect in the subgroup of patients with unknown onset time of stroke. The WAKE-412 
UP trial exclusively randomized patients with unknown onset stroke and demonstrated 413 
improved functional outcome with intravenous alteplase guided by MRI with DWI-FLAIR 414 
mismatch 6. The EXTEND trial included both patients in a late time window up to 9 hours of 415 
stroke and those with unknown onset stroke guided by penumbral imaging, and also showed 416 
a benefit of intravenous alteplase on functional outcome in these patients 9. Pooling 417 
individual data from only the patients with unknown onset stroke from these trials and two 418 
further randomized trials applying imaging biomarker selection to enroll patients resulted in a 419 
population of 843 patients with unknown onset stroke randomized based on advanced brain 420 
imaging. In this population, the adjusted OR for a favourable outcome with alteplase was 421 
1.48 (95% CI 1.07-2.06), with an absolute increase of 8% patients with favourable outcome 422 
translating into a number needed to treat of 12. This treatment effect is comparable to the 423 
treatment effect of intravenous alteplase within 4.5 hours of known stroke onset, with an aOR 424 
of 1.75 (95% CI 1.35-2.27) within 3 hours and of 1.26 (95% CI 1.05-1.51) after 3-4.5 hours 4. 425 
This confirms the validity and clinical utility of the concept of imaging-based selection of 426 
acute stroke patients for reperfusion treatment in cases where information on the time of 427 
symptom onset is not available.  428 
The trials included in this meta-analysis differed in design and imaging inclusion criteria but 429 
they all relied on imaging biomarkers beyond non-contrast CT and vessel imaging. WAKE-430 
UP and THAWS applied the DWI-FLAIR mismatch concept and randomized patients if MRI 431 
showed a mismatch between an acute ischemic lesion that was visible on DWI while there 432 
was no marked parenchymal hyperintensity on FLAIR based on visual judgement, indicating 433 
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an ischemic lesion age of less than 4.5 hours and the absence of severe and irreversible 434 
tissue damage 5. EXTEND and ECASS-4 used the concept of penumbral imaging for patient 435 
selection. They randomized patients who showed a relevant amount of salvageable brain 436 
tissue defined by a limited infarct core surrounded by a larger area of critically hypoperfused 437 
tissue as shown by perfusion-diffusion MRI or CT perfusion mismatch 12, similar to the 438 
approach used to guide endovascular stroke treatment in late or unknown time-window in 439 
two recent trials 10,11.  440 
This meta-analysis indicates that both concepts of imaging biomarker selection allow for 441 
effective identification of patients for reperfusion treatment after ischemic stroke. 442 
Nevertheless, there are inherent advantages and disadvantages of these concepts. DWI-443 
FLAIR mismatch requires MRI, but does not need perfusion imaging. It does not require any 444 
postprocessing but is effective with simple visual judgement of routine MRI sequences with a 445 
high interrater agreement as compared to quantitative evaluation by measurement of FLAIR 446 
signal intensity 21. Moreover, the DWI-FLAIR mismatch allows for treatment of patients with 447 
lacunar strokes, a subgroup of the WAKE-UP trial in whom the treatment effect of alteplase 448 
was similar compared to patients with other subtypes of stroke 22. These patients would not 449 
have met criteria of a relevant amount of salvageable tissue in perfusion-based penumbral 450 
mismatch imaging. On the other hand, penumbral mismatch may identify patients with 451 
salvageable tissue despite already marked hyperintensity on FLAIR and thus increase of the 452 
rate of patients treated with thrombolysis 23. For clinical practice, we conclude that any of the 453 
mismatch concepts is effective and can be recommended for guiding intravenous 454 
thrombolysis with alteplase in unknown onset stroke. 455 
Our meta-analysis showed increased rates of sICH with alteplase treatment, which was 456 
expected based on the results of previous pooled analysis of stroke thrombolysis trials 4. The 457 
increased risk of sICH corresponds to the biological effects of alteplase but also relates to 458 
higher rates of reperfusion 24. The overall small rate of 3% of intracranial haemorrhages with 459 
alteplase in this population of unknown onset stroke is comparable to the 3.5% rate of sICH 460 
according to SITS-MOST definition in the pooled analysis of stroke thrombolysis trials in 461 
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patients with known onset 4. It is reassuring that no excess of intracerebral haemorrhages is 462 
observed in unknown onset strokes compared to those with known onset. We also observed 463 
an increase in the mortality with alteplase treatment (6% vs. 3% in the control group), while 464 
rates of severe disability or death were numerically lower with alteplase, and rates of death 465 
and bedridden or nursing home outcomes were comparable for both treatment groups. 466 
Slightly increased mortality is not unexpected, as a significant increase of early deaths has 467 
been reported in the previous pooled analysis of stroke thrombolysis trials 4, which at least 468 
partially can be related to an increased rate of fatal intracerebral haemorrhage. In our 469 
analysis, 7/27 (26%) deaths in the alteplase group were attributable to SICH and thus 470 
possibly related to treatment with alteplase, while the majority of deaths were considered 471 
unrelated and of non-neurological cause. The increased mortality did not negate the net 472 
benefit of intravenous alteplase, as the analysis of functional outcome across the entire 473 
range of the mRS including death showed a significant benefit with overall better functional 474 
outcome with alteplase treatment. 475 
Our analysis did not identify a significant treatment heterogeneity in any relevant subgroups 476 
but confirmed a consistent treatment effect across a wide range of subgroups. Subgroup 477 
analyses also revealed no interaction of treatment effect with vessel occlusion. We also 478 
observed a significant treatment benefit in the subgroup of patients with a large vessel 479 
occlusion with an aOR of 2.35 (95% CI 1.04-5.32). This finding is of clinical importance and 480 
reinforces the finding in the previous perfusion mismatch meta-analysis of clear benefit of 481 
alteplase in large vessel occlusion 12. Doubts concerning the efficacy of intravenous alteplase 482 
in large vessel occlusion together with an assumed increased risk for intracranial 483 
haemorrhage have led to questioning the rationale for intravenous thrombolysis in these 484 
patients prior to thrombectomy 25. The results of our pooled analysis support treatment with 485 
alteplase in patients with LVO and unknown time of onset stroke, especially if patients 486 
present to centres where thrombectomy is not immediately available. 487 
Our meta-analysis has limitations. We cannot draw any inference on possible effects of the 488 
different dose of alteplase, as the THAWS trial was the only trial that used the lower dose of 489 
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0.6 mg/kg alteplase. Thus, we cannot separate a possible interaction of treatment effect with 490 
alteplase dose from overall trials’ effects. This is even more important, as the THAWS trial 491 
differed from the others in that it was the only trial that was not placebo-controlled but open-492 
label and, resulting from this design, allowed for early use of antithrombotic medication in the 493 
control group. Beyond early termination and the trial being underpowered, these factors 494 
might have been reasons why this individual trial was neutral 17. Moreover, all four 495 
randomized trials were terminated early, either due to cessation of funding (WAKE-UP), new 496 
evidence (EXTEND, THAWS), or change of clinical practice (ECASS-4). All of these are 497 
external reasons, thus, the potential bias is low, but early termination resulted in an overall 498 
smaller number of patients available for this individual patient data meta-analysis. With a 499 
sample size of 843 patients, statistical power to provide adjusted treatment-effect estimates 500 
for smaller subgroups was still limited, as reflected by wide 95% confidence intervals for 501 
some of the subgroup analyses. As the majority of patients included in this meta-analysis 502 
had rather mild to moderate strokes with a median NIHSS score of 7, results may not be 503 
generalizable to patients with severe stroke and large core. Finally, although we observed no 504 
heterogeneity of treatment effect between the trials, we have to consider that the results of 505 
the meta-analysis are to some extent driven by the WAKE-UP trial, representing almost 60% 506 
of the patients included in the analysis. 507 
The requirement for advanced imaging beyond non-contrast CT and vessel imaging, i.e., 508 
either perfusion CT or MRI, may currently still represent a potential limitation for 509 
implementation of the studied treatment approach in some regions or hospitals. However, 510 
given the recent evidence from WAKE-UP and EXTEND, together with the evidence for 511 
effective imaging-guided endovascular stroke treatment in an extended or unknown time-512 
window, advanced brain imaging has to be considered a requirement for providing state of 513 
the art evidence based stroke treatment 10,11. The results this meta-analysis should further 514 
support efforts to make these necessary imaging techniques more widely available to provide 515 
access to this effective treatment to as many stroke patients as possible. 516 
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In conclusion, intravenous alteplase improved functional outcome in unknown onset stroke 517 
patients selected by imaging biomarkers from MRI or CT perfusion. A net benefit was 518 
observed across the entire range of functional outcome despite an increased risk of sICH 519 
and higher mortality with alteplase. Treatment benefit was consistent across a wide range of 520 
subgroups including patients with large vessel occlusion. This individual patient data meta-521 
analysis extends the evidence from individual trials and supports the use of imaging 522 
biomarkers to guide treatment with intravenous alteplase in patients with an unknown time of 523 
stroke onset. 524 
 525 
  526 
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 527 
Panel: Research in context 528 
Evidence before this study 529 
We did a systematic review before 21 September 2020 for randomised trials of 530 
intravenous alteplase versus standard of care or placebo in adults with acute 531 
ischemic stroke and unknown time of symptom onset using advanced brain imaging 532 
with either penumbral imaging (i.e., perfusion-diffusion MRI or perfusion CT) or MRI-533 
based tissue-clocking (i.e., a mismatch on MRI between a visible lesion on diffusion 534 
weighted imaging [DWI] and no marked parenchymal hyperintensity on fluid 535 
attenuated inversion recovery [FLAIR], DWI-FLAIR mismatch) with >20 patients. This 536 
identified four trials. The WAKE-UP trial randomized 503 patients with unknown time 537 
of onset stroke to intravenous alteplase or placebo if they had DWI-FLAIR mismatch 538 
in visual assessment and found a significant better functional outcome in patients 539 
treated with alteplase compared with placebo. The EXTEND trial randomized 225 540 
patients with late time window or unknown time of onset  stroke to alteplase after 541 
automated CT or MRI perfusion imaging and demonstrated higher rates of excellent 542 
functional outcome compared with placebo. The THAWS trial randomized 131 543 
patients with unknown time of onset stroke to treatment with alteplase or standard of 544 
care based on visual assessment of the DWI-FLAIR mismatch and was neutral, but 545 
was underpowered. The ECASS4-EXTEND trial randomly assigned 119 patients with 546 
late time window or unknown time of onset stroke and penumbral mismatch on 547 
perfusion-diffusion MRI and was neutral, but also was underpowered. However, all 548 
four studies were stopped early for different reasons, and had only modest sample 549 
sizes limiting strength and precision of the findings. 550 
Added value of this study 551 
This systematic review and individual patient data meta-analysis of four randomised 552 
trials quantifies the benefits and risks of intravenous alteplase for patients with 553 
unknown time of onset stroke. Intravenous alteplase resulted in higher rates of 554 
excellent functional outcome defined as a score of 0-1 on the modified Rankin Scale 555 
(mRS) at 90 days than placebo or standard care. A net benefit was observed for all 556 
functional outcomes across the entire range of the mRS despite an increased risk of 557 
sICH. While there were numerically higher rates of death with alteplase, rates of 558 
severe disability or death (mRS 4-6) were numerically lower with alteplase. Subgroup 559 
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analysis did not identify a significant treatment heterogeneity in relevant subgroups 560 
but confirmed a consistent treatment effect across a wide range of subgroups. We 561 
also observed a significant treatment benefit in the subgroup of patients with a large 562 
vessel occlusion. 563 
Implications of all the available evidence 564 
Stroke patients with unknown time of symptom onset DWI-FLAIR mismatch or 565 
perfusion mismatch, who receive treatment with intravenous alteplase have a better 566 
functional outcome at 90 days than patients receiving placebo or standard of care. 567 
There was a net benefit for all functional outcomes and also comparable rates of 568 
severe disability or death, despite an increased risk of sICH and numerically higher 569 
mortality with alteplase. These results extend the findings from individual trials and 570 
provide level 1a evidence for the use of brain imaging beyond non-contrast CT to 571 
guide treatment with intravenous alteplase in patients with an unknown time of stroke 572 
onset.  573 
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Tables 765 
 766 
Table 1: Demographic and Baseline Characteristics of the Patients  767 
 768 




Age – years   
Mean (SD) 68.5 (12.2) 68.5 (12.7) 
Male sex – number (%) 268 (63%) 253 (61%) 
Reason for unknown time of symptom onset – number 
(%) 
  
Overnight-sleep 385 (90%) 366 (88%) 
Other 44 (10%) 48 (12%) 
Time between last seen well and symptom recognition – 
hours  
  
Median, interquartile range 7.0 (4.7-9.0) 7.0 (5.0-9.0) 
Medical history / risk factors – no. (%)   
Arterial hypertension 259/428 (61%) 254/412 (60%) 
Diabetes mellitus 83/424 (20%) 69/413 (17%) 
Hypercholesterolemia * 116/311 (63%) 108/301 (64%) 
Atrial fibrillation 86/427 (20%) 72/408 (18%) 
History of ischemic stroke or TIA * 45/323 (14%) 45/310 (15%) 
Pretreatment with antiplatelets – no. (%) 125/397 (32%) 132/383 (35%) 
NIHSS score    
Median, interquartile range 7 (4-12) 7 (4-12) 
Imaging modality: CT 65 (15%) 64 (16%) 
Imaging modality: MRI 364 (85%) 350 (85%) 
Vessel occlusion on baseline CT- or MR-angiography †   
Any vessel occlusion – no. (%) 174/391 (45%) 168/380 (44%) 
Large vessel occlusion – no. (%) 99/391 (25%) 90/380 (24%) 
Penumbral mismatch present 112/208 (45%) 109/197 (55%) 
DWI-FLAIR mismatch present 327/345 (95%) 315/334 (94%) 
Alteplase dose 0.9 mg/kg bodyweight 359 (84%) 353 (85%) 
Alteplase dose 0.6 mg/kg bodyweight 70 (16%) 61 (15%) 
Time from symptom recognition to treatment initiation – 
hours  
  
Median, interquartile range 3.3 (2.6-4.1) 3.4 (2.7-4.1) 
Time between last seen well and treatment initiation – 
hours  
  
Median, interquartile range 10.6 (8.6-12.4) 10.5 (8.4-12.3) 
 769 
SD denotes standard deviation; TIA = transient ischemic attack; NIHSS = National Institutes of Health 770 
Stroke Scale; * not recorded in ECASS-4 and EXTEND; † not available for ECASS-4. 771 
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(95% CI) * 
p-value 
Primary Efficacy Outcome     
Favourable Outcome (mRS 0-1) 
at 90 days – no. (%) † 
199 (47%) 160 (39%) 1.49 (1.10-2.03) 0.011 
Secondary Efficacy Outcomes     
mRS score at 90 days ‡   1.38 (1.05-1.80) 0.019 
Independent Outcome (mRS 0-2) 
at 90 days – no. (%) † 
273 (65%) 239 (58) 1.50 (1.06-2.12) 0.022 
Safety Outcomes     
Death at 90 days – no. (%) † 27 (6%) 14 (3%) 2.06 (1.03-4.09) 0.040 
Death at 7 days – no. (%) 10 (2%) 4 (1%) 2.54 (0.78-8.32) 0.19 
Severe disability or death (MRS 
4-6) at 90 days – no. (%) † 
90 (21%) 102 (25%) 0.76 (0.52-1.11) 0.15 
Dependence or death (MRS 3-6) 
at 90 days – no. (%) † 
147 (35%) 170 (42%) 0.67 (0.47-0.94) 0.022 
Symptomatic intracerebral 
haemorrhage – no. (%) 
11 (3%) 2 (<1%) 5.58 (1.22-25.50) 0.024 
Parenchymal haemorrhage type 
2 (PH-2) – no. (%) ‡ 
11 (3%) 3 (1%) 3.51 (0.98-12.60) 0.068 
 775 
mRS denotes modified Rankin scale 776 
* Odds ratios were adjusted for age and symptom severity at baseline. 777 
† Numbers are given for patients with available data on the primary efficacy endpoint; mRS at day 90 778 
was missing for 9 patients in the alteplase and 5 in the control group; missing primary outcome values 779 
were replaced using multiple imputation. 780 
‡ Radiological assessment of parenchymal haemorrhage type 2 (PH-2) was available for 320 patients 781 
in the alteplase and 307 in the control group 782 
 783 
 784 
  785 
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Figure legends 787 
 788 
Figure 1. Distribution of Scores on the modified Rankin Scale at 90 Days. 789 
Scores on the modified Rankin Scale range from 0 to 6, with 0 indicating no symptoms, 1 no 790 
clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe 791 
disability, 5 severe disability, and 6 death. Numbers indicate the proportion of patients (%) 792 
per category. 793 
 794 
 795 
Figure 2. Subgroup analyses 796 
Forest plots for the primary outcome of favourable outcome (modified Rankin Scale 0–1 at 797 
90 days) in all patients for predefined subgroups. 798 
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